Clinical Trials Browser

Approved for marketing × Leukemia, Lymphocytic, Chronic, B-Cell × idelalisib × Clear all

NCT02136511 2014-10-28

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Approved for marketing

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell